This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Jan;105(2):i-iii.

doi: 10.1111/j.1464-410X.2009.09168.x.

Redefining personalized medicine in the postgenomic era: developing bladder cancer therapeutics with proteomics

Kevin D Blanchet

PMID: 20078597
DOI: 10.1111/j.1464-410X.2009.09168.x

Redefining personalized medicine in the postgenomic era: developing bladder cancer therapeutics with proteomics

Kevin D Blanchet. BJU Int. 2010 Jan.

. 2010 Jan;105(2):i-iii.

doi: 10.1111/j.1464-410X.2009.09168.x.

Author

Kevin D Blanchet

PMID: 20078597
DOI: 10.1111/j.1464-410X.2009.09168.x

No abstract available

PubMed Disclaimer

Similar articles

Urinary bladder tumor markers.
Lokeshwar VB, Selzer MG. Lokeshwar VB, et al. Urol Oncol. 2006 Nov-Dec;24(6):528-37. doi: 10.1016/j.urolonc.2006.07.003. Urol Oncol. 2006. PMID: 17138134 Review.
Network views for personalized medicine.
Vlahou A. Vlahou A. Proteomics Clin Appl. 2013 Jun;7(5-6):384-7. doi: 10.1002/prca.201200121. Epub 2013 May 10. Proteomics Clin Appl. 2013. PMID: 23532915
Can a point-of-care urine protein assay monitor bladder cancer recurrence?
O'donnell MA. O'donnell MA. Nat Clin Pract Oncol. 2006 Sep;3(9):482-3. doi: 10.1038/ncponc0589. Nat Clin Pract Oncol. 2006. PMID: 16955086 No abstract available.
Molecular markers in bladder cancer.
Shariat SF, Karam JA, Lerner SP. Shariat SF, et al. Curr Opin Urol. 2008 Jan;18(1):1-8. doi: 10.1097/MOU.0b013e3282f1c5c1. Curr Opin Urol. 2008. PMID: 18090481 Review.
Application of 2D-DIGE in cancer proteomics toward personalized medicine.
Kondo T, Hirohashi S. Kondo T, et al. Methods Mol Biol. 2009;577:135-54. doi: 10.1007/978-1-60761-232-2_11. Methods Mol Biol. 2009. PMID: 19718514

See all similar articles

Cited by

Nanotheranostics: A Possible Solution for Drug-Resistant Staphylococcus aureus and their Biofilms?
Mosselhy DA, Assad M, Sironen T, Elbahri M. Mosselhy DA, et al. Nanomaterials (Basel). 2021 Jan 2;11(1):82. doi: 10.3390/nano11010082. Nanomaterials (Basel). 2021. PMID: 33401760 Free PMC article. Review.
Versatile Nanosystem-Based Cancer Theranostics: Design Inspiration and Predetermined Routing.
Opoku-Damoah Y, Wang R, Zhou J, Ding Y. Opoku-Damoah Y, et al. Theranostics. 2016 Apr 28;6(7):986-1003. doi: 10.7150/thno.14860. eCollection 2016. Theranostics. 2016. PMID: 27217832 Free PMC article. Review.
Development and applications of photo-triggered theranostic agents.
Rai P, Mallidi S, Zheng X, Rahmanzadeh R, Mir Y, Elrington S, Khurshid A, Hasan T. Rai P, et al. Adv Drug Deliv Rev. 2010 Aug 30;62(11):1094-124. doi: 10.1016/j.addr.2010.09.002. Epub 2010 Sep 19. Adv Drug Deliv Rev. 2010. PMID: 20858520 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information